François Thomas

Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.

INSERM Transfert SA is a Venture Capital firm, a subsidiary of Institut National de la Sant? et de la Recherche M?dicale founded in 2000. INSERM Transfert SA is headquartered in Paris, France.

Cardiawave SA develops non-invasive medical device to treat a heart condition called aortic stenosis. The company was founded by Emmanuel Messas, Benjamin Bertrand, Mickaël Tanter, Mathieu Pernot and Mathias Fink on October 21, 2014 and is headquartered in Paris, France.

Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

Biomodex SAS develops 3D printed surgical simulators for medical education and patient-specific preoperative planning. It offers simulators for surgical procedures such as bone drilling, soft tissue suturing, medical device implantation, and sizing. The company was founded by Thomas Marchand and Sidarth Radjou on January 22, 2015 and is headquartered in Paris, France.

Institut Gustave Roussy EURL is a cancer research and treatment center that places innovation at the heart of its services. The private company is based in Chevilly-Larue, France, and has subsidiaries in France. The center has strong partnerships at national and international levels to provide high-value care to all its patients. Patients' rights are protected and guaranteed to ensure their autonomy, respect for their individual liberties, and dignity within the hospital.

Sofimac Régions SAS is a Private Equity/Venture Capital firm, a subsidiary of Sofimac Investment Managers SAS founded in 1978. Sofimac Régions is headquartered in Clermont-Ferrand.

Axilum Robotics SAS develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures. Its first project is a robot to assist psychiatrists and neurologists for Transcranial Magnetic Stimulation (TMS). The firm's project TMS is a painless, non invasive medical technique that applies high intensity magnetic impulses to cortex areas by placing a coil on the surface of the head. The company was founded by Bernard Bayle, Michel Berg, Michel de Mathelin, Romuald Ginhoux, Benjamin Maurin and Pierre Renaud in April 2011 and is headquartered in Strasbourg, France.

Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France.

INSERM Transfert Initiative SAS is a venture capital fund that invests in companies located in France. It targets startups from the life sciences and biotechnology sectors, developing new medical practices with a strong intellectual property. It invests between €1 million and €3 million per company during mostly at pre-seed, seed and early-stages.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.